Abstract # 58 : Modulation of soluble c-Met, bone turnover markers, angiogenic factors, and c-Met in men with mCRPC treated with cabozantinib. ( D13 )
Paul G. Corn - The University of Texas MD Anderson Cancer Center
What makes this abstract particularly compelling is that Dr Korn published in the BJC in October 2012:
"Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials"
...and has apparently concluded that a metabolite of bone turnover (BAP) may be predictive of overall survival in advanced mCRPC. This presentation could provide some real entertainment value for Cabo.